Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients
AIDS Research and Human Retroviruses · 2023
DOI: 10.1089/aid.2022.0130 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift AIDS Research and Human Retroviruses, 2023. Verfasst von Edgar Pérez-Barragán und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Infectología, Hospital General de Zona N° 48, Ciudad de México, México. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Recent studies suggest that the introduction of antiretroviral agents such as integrase strand transfer inhibitors (INSTI) may lead to weight gain in people living with HIV (PLHIV). In this retrospective observational study, we report the weight changes observed in virologically suppressed HIV patients after 12 months of switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF) due to a national change in public policy in Mexico. Patients on prior regimens based on TDF/FTC or ABC/3TC plus non-nucleoside retrotranscriptase inhibitor, INSTI, or protease inhibitor were included. In the 399 patients analyzed, a significant weight increase was found, as well as an increase in body mass index (BMI), total cholesterol, low-density lipoprotein cholesterol (LDL-C), glucose, creatinine, and CD4 + cells after 12 months of switching treatment (all p ≤ .001). Mean weight gain was 1.63 kg [confidence interval (95% CI): 1.14–2.11], whereas the average percentage of weight gained was 2.5% (95% CI: 1.83–3.17). After considering the confounding effect of baseline weight status, the change in weight and BMI did not present significant differences between any of the prior treatment schemes. In conclusion, PLHIV switching to BIC/F/TAF therapy experienced weight gain after the first year of switching treatment. Although this weight gain could be due to the switch in treatment regimen, it cannot be excluded that it was caused by other factors since no comparable control group could be used for comparison.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Infectología, Hospital General de Zona N° 48, Ciudad de México, México.
- Servicio de Medicina Interna, Hospital General de Zona N° 48, Ciudad de México, México.
- División de Posgrado, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.
- Dirección de Investigación, Instituto Nacional de Geriatría, Ciudad de México, México.
- Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, México.
- Servicio de Infectología, Hospital de Infectología, Centro Médico Nacional La Raza, Ciudad de México, México.
ORCID-Profile: Edgar Pérez-Barragán, Mónica Fernanda Guevara-Maldonado, Javier Mancilla-Galindo, Ashuin Kammar-García, Alejandro Ortiz-Hernández, José Antonio Mata-Marín, Samantha Pérez-Cavazos
Zitieren
APA
Pérez-Barragán, E., Guevara-Maldonado, M. F., Mancilla-Galindo, J., Kammar-García, A., Ortiz-Hernández, A., Mata-Marín, J. A., & Pérez-Cavazos, S. (2023). Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients. AIDS Research and Human Retroviruses. https://doi.org/10.1089/aid.2022.0130
Vancouver
Pérez-Barragán E, Guevara-Maldonado MF, Mancilla-Galindo J, Kammar-García A, Ortiz-Hernández A, Mata-Marín JA, et al. Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients. AIDS Research and Human Retroviruses. 2023. doi:10.1089/aid.2022.0130
BibTeX
@article{PrezBarragn2023,
author = {Pérez-Barragán, Edgar and Guevara-Maldonado, Mónica Fernanda and Mancilla-Galindo, Javier and Kammar-García, Ashuin and Ortiz-Hernández, Alejandro and Mata-Marín, José Antonio and Pérez-Cavazos, Samantha},
title = {Weight Gain After 12 Months of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV Patients},
journal = {AIDS Research and Human Retroviruses},
year = {2023},
doi = {10.1089/aid.2022.0130}
}
EUVIMED